Indo Borax & Chemicals is buying the controlling 64.26% promoter stake for ₹246.12 crore, or ₹103.22 per share. The SEBI-mandated open offer to minority shareholders is much higher, at ₹157.27. The market was near ₹170–174.
Kronox Lab Sciences makes high-purity fine chemicals for pharmaceuticals, biotechnology and research. Its portfolio spans over 185 specialized products sold in more than 20 countries. Incorporated in 2008, it listed in June 2024.
Three Vadodara units hold 7,242 tonnes per annum capacity. Global pharma regulatory requalification makes customers reluctant to switch. Over a third of clients have stayed over five years. The company operates without long-term contracts and with zero borrowings.
Current plants are at their practical ceiling, leaving revenue flat between FY23 and FY26. Dahej Unit IV in Gujarat will add 18,000 TPA, lifting total capacity to 25,242 TPA—about a 250% jump. Commercial output is expected around FY28.
From FY23 to FY25, operating profit rose from ₹21.71 crore to ₹33.13 crore, pushing operating margin from about 23% to 33%. Profit after tax grew from ₹16.40 crore to ₹25.47 crore. The company remains debt-free with ROE above 35%.
On August 20, 2026, Indo Borax & Chemicals announced board approval to acquire 2,38,44,000 shares from promoters. The ₹103.22-per-share deal totals ₹246.12 crore. Zenrock Chemicals is the person acting in concert. The open offer seeks up to 95.70 lakh more shares.
Indo Borax is acquiring 64.26% of Kronox from the founding promoters. The effective price including transition support fees is ₹105.87 per share, while the open offer to minorities is ₹157.27, creating a hard floor near the stock's recent range.
The open offer provides ₹157.27 downside protection. Kronox's 48.9% ROCE dwarfs peers like Aether at 11.9%, Navin at 20.9%, Pidilite at 31.0%. That efficiency matters as Dahej capex begins under new ownership.
Top ten customers contribute 41–45% of revenue; top twenty products drive a large share of turnover. No long-term contracts mean demand can shift quickly. Dahej output needs customer requalification and may not generate meaningful revenue until FY28 or FY29, adding integration risk after the takeover.
Kronox is a debt-free, high-margin niche chemical maker at a critical juncture: new ownership, a 250% capacity plan, and a long wait for Dahej. The full article maps the open offer, financials, and competitive moat in detail.
Read the full analysis →